Sanofi

SNY • Drug Manufacturers - General

$44.24

▼ -0.09 (-0.20%)

Current price

EarningsLatest report: Mar 31, 2026

HIGHLY FAVORABLE PROFILEExcellentConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.

Market Cap

$106.55B

Growth

6.6%

Cash Flow

5/5

Trend

Stable

Evidence

Stable or improving margins · 16.7%Positive revenue growth · 5.2%Positive free cash flow · 4.16Consistent free cash flow · 5/5Reasonable earnings multiple · 12.88

Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: Apr 23, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$44.24

Change-0.20%

Shares Out2.41B

Market Cap$106.55B

52W Range40.89 - 52.68

Beta0.28

P/E16.04

P/S9.21

P/B1.42

P/FCF0.00

EV/Sales10.22

EV/EBITDA42.29

Price$44.24

Change-0.20%

Shares Out2.41B

Market Cap$106.55B

52W Range40.89 - 52.68

Beta0.28

P/E16.04

P/S9.21

P/B1.42

P/FCF0.00

EV/Sales10.22

EV/EBITDA42.29

EV/FCF0.00

Earnings Yield6.24%

FCF Yield0.00%

Dividend Yield0.00%

Gross Margin72.07%

Oper. Margin20.54%

Profit Margin16.72%

Debt/Eq0.31

Current Ratio1.09

Quick Ratio0.29

Revenue 5Y6.57%

FCF 5Y10.88%

Target$49.50

Target Upside11.89%

Target Median$49.50

Target Range49.00 - 50.00

Volume10.18M

Avg Volume3.26M

EPS Surprise0.04

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

85/100

Financial Strength

Debt, cash, stability

64/100

Growth Potential

Revenue and expansion

71/100

Price Attractiveness

Cheap or expensive today

87/100

Why this score▼

Stable or improving margins · 16.7%Positive revenue growth · 5.2%Positive free cash flow · 4.16Consistent free cash flow · 5/5Reasonable earnings multiple · 12.88Manageable debt level · 0.31

Analyst view

Analyst sentiment and price target

SNY

Analyst sentiment

Based on 27 analyst votes · 2026-09-05

70/100

Bullish

Hold

Bearish

Price Target

2026-07-31

Low

$49.00

Mean

$49.50

Median

$49.50

High

$50.00

Company Overview

IPO: 7/1/2002

Industry: Drug Manufacturers - General

P/B i: 1.42

Debt / Equity i: 0.31

Operating Margin: 20.54%

Net Margin: 16.72%

ROE i: -

ROIC: -

Financial Health

Score13 / 20

Debt / Equity: 0.31

Current Ratio: 1.09

Quick Ratio: 0.29

Status: Good

Warnings

Weak quick ratio

🧾

No insider activity

No recent insider transactions available.

About the Company

Sanofi

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Source - link

Peers

AMGN BMY CELG-RI CVS GILD GSK HCA MDT PFE VRTX

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Brokerages Set Sanofi (NASDAQ:SNY) Price Target at $49.50

Sanofi (NASDAQ: SNY - Get Free Report) has earned a consensus recommendation of "Hold" from the fifteen analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation, three have given a buy recommendation and two have assigned a

Defense World

SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?

Sanofi's stock trades above key moving averages as Dupixent and new drugs drive growth, while pipeline setbacks and vaccine weakness weigh.

Zacks Investment Research

US FDA approves updated COVID vaccines for 2026-27 season

The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies ‌said on Thursday, after an advisory panel recommended that the shots should target the dominant XFG variant.

Reuters

Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity?

The FDA just approved the company's on-body injector for its blood cancer drug. Analysts see upside potential ahead for shares of the French pharmaceutical giant.

The Motley Fool

Sanofi: Trump's Vaccine Policy Won't Break The Story

On August 10, Trump signed Executive Order 14420. But I believe the pressure on Sanofi stock from Trump's Gold Standard Childhood Vaccine Recommendations will be temporary. Sanofi is trading at a significant discount, with a non-GAAP P/E ratio [FWD] of 9.2x, 53.2% below the sector median.

Seeking Alpha

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-04-23	1.06	1.1	0.04
2026-01-29	0.84	0.89	0.05
2025-10-24	1.6	1.7	0.1
2025-07-31	0.96	0.9	-0.06
2025-04-24	0.9	0.94	0.04
2025-01-30	0.71	0.7	-0.01
2024-10-25	1.35	1.57	0.22
2024-07-25	0.86	0.93	0.07
2024-04-25	0.94	0.97	0.03
2024-02-01	0.94	0.89	-0.05
2023-10-27	1.37	1.39	0.02
2023-07-28	1.55	0.95	-0.6